Andes Biotechnologies' therapeutics use antisense technologies to selectively destroy cancer cells without affecting normal cells, and the company has an active investigational new drug (IND) application in the United States. Founded in 2008 and located in Santiago, Chile, Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers.